Recent Updates
Recently added Catalysts

pharmacokinetic interaction

Phase 1

Healthy Subjects | Small molecule | Other |Pfizer, Inc.|Last Updated: Aug 7, 2009

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedUNCONTROLLED
Total Trials1
Total Enrollment -

FDA Designations

No designations recorded

Clinical trial landscape

pharmacokinetic interaction · 1 trial · 1 indication

Phase 1 1
NCT00369304Study Evaluating the Pharmacokinetics of the Potential Drug Interaction Between CYP2C9 Inhibitor and SubstrateHealthy Subjects
COMPLETED- Analytics
PHASE1COMPLETED
Study Evaluating the Pharmacokinetics of the Potential Drug Interaction Between CYP2C9 Inhibitor and Substrate
Healthy Subjects
NCT00369304-
Unlock trial analytics

Study Endpoints

Primary Endpoints

To evaluate the effects of a single oral dose of AGG-523 on the pharmacokinetic profile of a single oral dose of tolbutamide in healthy subjects.
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeTREATMENT

Interventions

NameTypeDescription
pharmacokinetic (how the body absorbs and eliminates) interactionDRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 50 Years
SexALL
Healthy VolunteersYes

1. Men and women, aged 18 to 50 years. Women of non-childbearing potential may be included. 2. Body mass index in the range of 18 to 30 kg/meter squared and body weight equal to or greater than 50 kg. 3. Healthy as determined by the investigator on the basis of medical history, physical examination,...

Unlock Eligibility Criteria